Apex Biotechnology Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Apex Biotechnology.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth	22.4%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	16 Jul 2024

Recent future growth updates

Recent updates

Some May Be Optimistic About Apex Biotechnology's (TWSE:1733) Earnings

Nov 21

Apex Biotechnology (TWSE:1733) Will Be Hoping To Turn Its Returns On Capital Around

Aug 06

Apex Biotechnology's (TWSE:1733) Conservative Accounting Might Explain Soft Earnings

Mar 21

Apex Biotechnology's (TPE:1733) Returns On Capital Not Reflecting Well On The Business

Apr 17

Is Apex Biotechnology (TPE:1733) Using Too Much Debt?

Mar 30

Is Apex Biotechnology Corp. (TPE:1733) A Good Fit For Your Dividend Portfolio?

Mar 10

Is Apex Biotechnology Corp.'s (TPE:1733) Stock On A Downtrend As A Result Of Its Poor Financials?

Feb 17

A Look At Apex Biotechnology's (TPE:1733) Share Price Returns

Jan 27

Returns On Capital At Apex Biotechnology (TPE:1733) Paint An Interesting Picture

Jan 06

These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely

Dec 16

Is Apex Biotechnology Corp.'s (TPE:1733) 4.5% Dividend Worth Your Time?

Nov 22

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Apex Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TWSE:1733 - Analysts future estimates and past financials data (TWD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2024	1,891	105	271	291	1
9/30/2024	1,808	105	264	291	N/A
6/30/2024	1,711	109	241	265	N/A
3/31/2024	1,691	109	294	315	N/A
12/31/2023	1,677	116	205	230	N/A
9/30/2023	1,775	144	95	121	N/A
6/30/2023	1,968	170	22	55	N/A
3/31/2023	2,159	172	-13	20	N/A
12/31/2022	2,244	182	-14	27	N/A
9/30/2022	2,297	220	25	72	N/A
6/30/2022	2,201	220	33	73	N/A
3/31/2022	2,077	214	16	54	N/A
12/31/2021	2,132	202	150	180	N/A
9/30/2021	2,025	154	284	311	N/A
6/30/2021	2,025	113	274	306	N/A
3/31/2021	2,070	117	298	340	N/A
12/31/2020	2,005	95	232	281	N/A
9/30/2020	2,217	143	276	333	N/A
6/30/2020	2,173	103	353	416	N/A
3/31/2020	2,186	104	269	324	N/A
12/31/2019	2,199	114	406	463	N/A
9/30/2019	2,052	-4	137	207	N/A
6/30/2019	2,142	83	159	241	N/A
3/31/2019	2,098	100	136	216	N/A
12/31/2018	2,044	95	-15	68	N/A
9/30/2018	1,996	177	92	150	N/A
6/30/2018	1,919	129	N/A	183	N/A
3/31/2018	1,841	142	N/A	164	N/A
12/31/2017	1,795	86	N/A	71	N/A
9/30/2017	1,692	-90	N/A	96	N/A
6/30/2017	1,617	-110	N/A	118	N/A
3/31/2017	1,706	-103	N/A	165	N/A
12/31/2016	1,763	3	N/A	298	N/A
9/30/2016	1,874	209	N/A	436	N/A
6/30/2016	1,941	316	N/A	394	N/A
3/31/2016	1,855	292	N/A	423	N/A
12/31/2015	1,847	262	N/A	472	N/A
9/30/2015	1,863	271	N/A	455	N/A
6/30/2015	1,821	224	N/A	405	N/A
3/31/2015	1,840	248	N/A	340	N/A
12/31/2014	1,789	273	N/A	268	N/A
9/30/2014	1,648	220	N/A	218	N/A
6/30/2014	1,674	209	N/A	121	N/A
3/31/2014	1,728	307	N/A	305	N/A
12/31/2013	1,829	371	N/A	485	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1733's forecast earnings growth is above the savings rate (1.1%).

Earnings vs Market: Insufficient data to determine if 1733's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 1733's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1733's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 1733's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 1733's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 00:56
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Apex Biotechnology Corp. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jiahong Liu	E.Sun Securities Investment Consulting Co. Ltd.
Ryan Liu	IBTS Investment Consulting Co., Ltd.
Zhennan Lee	Jih Sun Securities Investment Consulting Co., Ltd.

Apex Biotechnology Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased to NT$26.00

Recent updates

Some May Be Optimistic About Apex Biotechnology's (TWSE:1733) Earnings

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Apex Biotechnology Corp. to Report Q3, 2024 Results on Nov 13, 2024

Now 21% overvalued

Insufficient new directors

Second quarter 2024 earnings: EPS exceeds analyst expectations

Apex Biotechnology (TWSE:1733) Will Be Hoping To Turn Its Returns On Capital Around

Apex Biotechnology Corp. to Report Q2, 2024 Results on Aug 09, 2024

New minor risk - Market cap size

First quarter 2024 earnings released: EPS: NT$0.29 (vs NT$0.36 in 1Q 2023)

Upcoming dividend of NT$1.10 per share

Apex Biotechnology Corp. to Report Q1, 2024 Results on May 10, 2024

Apex Biotechnology Corp. Approves Cash Dividend for 2023, Payable on June 14, 2024

Apex Biotechnology's (TWSE:1733) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings released

Apex Biotechnology Corp., Annual General Meeting, Apr 30, 2024

Investor sentiment deteriorates as stock falls 18%

Investor sentiment improves as stock rises 18%

Second quarter 2023 earnings released: EPS: NT$0.27 (vs NT$0.29 in 2Q 2022)

Upcoming dividend of NT$1.40 per share at 4.8% yield

Full year 2022 earnings released: EPS: NT$1.82 (vs NT$2.03 in FY 2021)

Price target decreased to NT$26.00

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of NT$1.30 per share

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: EPS NT$0.64 (vs NT$0.23 in 3Q 2020)

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Second quarter 2021 earnings released: EPS NT$0.23 (vs NT$0.27 in 2Q 2020)

Upcoming dividend of NT$1.09 per share

First quarter 2021 earnings released: EPS NT$0.34 (vs NT$0.12 in 1Q 2020)

Apex Biotechnology's (TPE:1733) Returns On Capital Not Reflecting Well On The Business

Is Apex Biotechnology (TPE:1733) Using Too Much Debt?

Full year 2020 earnings released: EPS NT$0.95 (vs NT$1.14 in FY 2019)

Is Apex Biotechnology Corp. (TPE:1733) A Good Fit For Your Dividend Portfolio?

Apex Biotechnology Corp., Annual General Meeting, May 28, 2021

Is Apex Biotechnology Corp.'s (TPE:1733) Stock On A Downtrend As A Result Of Its Poor Financials?

A Look At Apex Biotechnology's (TPE:1733) Share Price Returns

New 90-day low: NT$22.40

Returns On Capital At Apex Biotechnology (TPE:1733) Paint An Interesting Picture

New 90-day low: NT$23.70

These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely

Is Apex Biotechnology Corp.'s (TPE:1733) 4.5% Dividend Worth Your Time?

Third quarter 2020 earnings released: EPS NT$0.23

New 90-day low: NT$24.15

New 90-day low: NT$25.05

First half earnings released

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources